Cargando…

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells

BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent. In melanoma, the existence of a BRAF mutation is a main predictor for successful BRAF-targeted therapy. However, despite initial successes with these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arozarena, Imanol, Goicoechea, Ibai, Erice, Oihane, Ferguson, Jennnifer, Margison, Geoffrey P, Wellbrock, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079649/ https://www.ncbi.nlm.nih.gov/pubmed/24941944 http://dx.doi.org/10.1186/1476-4598-13-154

Ejemplares similares

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
por: Wellbrock, Claudia, et al.
Publicado: (2016)

Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy
por: Wellbrock, Claudia, et al.
Publicado: (2015)

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
por: Ferguson, Jennifer, et al.
Publicado: (2012)

Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth
por: Ferguson, Jennifer, et al.
Publicado: (2017)

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
por: Smith, Michael P., et al.
Publicado: (2013)

In melanoma, beta-catenin acts as suppressor of invasion through a cell-type specific mechanism
por: Arozarena, Imanol, et al.
Publicado: (2011)

Targeting MITF in the tolerance-phase
por: Arozarena, Imanol, et al.
Publicado: (2016)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
por: Wellbrock, Claudia, et al.
Publicado: (2008)

Cooperative behaviour and phenotype plasticity evolve during melanoma progression
por: Rowling, Emily J., et al.
Publicado: (2020)

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
por: Smith, Michael P., et al.
Publicado: (2016)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF(high)/AXL(low) melanoma
por: Smith, Michael P., et al.
Publicado: (2018)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei
por: Dewar, Simon, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021)

Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas
por: Giovanni, Ponti, et al.
Publicado: (2014)

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries
por: Pipek, Orsolya, et al.
Publicado: (2023)

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition
por: Young, Helen L., et al.
Publicado: (2017)

Chiral evasion and stereospecific antifolate resistance in Staphylococcus aureus
por: Wang, Siyu, et al.
Publicado: (2022)

Erratum to “Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanoma”
por: Ponti, Giovanni, et al.
Publicado: (2014)

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
por: Cristofani, Riccardo, et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia
por: Mkulama, Mtawa AP, et al.
Publicado: (2008)

Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer
por: Nduati, Eunice, et al.
Publicado: (2008)

Dual-Target Mycobacterium tuberculosis Inhibition: Insights into the Molecular Mechanism of Antifolate Drugs
por: Ramharack, Pritika, et al.
Publicado: (2023)

The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence
por: Borkowski, Piotr K., et al.
Publicado: (2016)

Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis
por: Hajian, Behnoush, et al.
Publicado: (2016)

BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
por: Oikonomou, Eftychia, et al.
Publicado: (2014)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Assessment of the Chemosensitizing Activity of TAT-RasGAP(317-326) in Childhood Cancers
por: Chevalier, Nadja, et al.
Publicado: (2015)

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)

In vitro chemosensitivity tests on xenografted human melanomas.
por: Bateman, A. E., et al.
Publicado: (1980)

Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan
por: Awab, Ghulam R, et al.
Publicado: (2013)

Antifolate Agents Against Wild and Mutant Strains of Plasmodium falciparum
por: Shaikh, M. S., et al.
Publicado: (2014)

Factors Influencing the Antifolate Activity of Synthetic Tea-Derived Catechins
por: Sáez-Ayala, Magalí, et al.
Publicado: (2013)

Folate transporter dynamics and therapy with classic and tumor-targeted antifolates
por: O’Connor, Carrie, et al.
Publicado: (2021)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan
por: Khattak, Aamer A, et al.
Publicado: (2013)

MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription
por: Liu, Tingting, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2fntdcpbpk8gql6f5e113v75rk